MLMC Therapeutics ApS: Financial statements 2024
CVR: 41277688
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
MLMC Therapeutics ApS (CVR 41277688) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -26,638 and a net result of DKK -134,525 compared with DKK -122,678 the year before. Equity in the 2024 report amounted to DKK -339,073.
- Gross Profit
- DKK -26,638
- Profit/Loss
- DKK -134,525
- Equity
- DKK -339,073
- Total Assets
- DKK 159,201
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -27 t. | -135 t. | -339 t. | - |
| 2023 | - | -26 t. | -123 t. | -205 t. | - |
| 2022 | - | -30 t. | -90 t. | -82 t. | - |
| 2021 | - | -20 t. | -54 t. | 8 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
MLMC Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -25,639, and the net result was DKK -122,678.
About MLMC Therapeutics ApS
MLMC Therapeutics ApS is a Danish company of the type Anpartsselskab based in Kastrup, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michael Henrik Stadi. The board consists of Martin Kiener (chair), Hanne Damgaard Jensen and Peter Gudmund Nielsen. The company's owners include Ritika Singh Petersen, Sriram Thoppe Rajendran and FOMT HOLDING ApS. According to the 2021 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -30,768 and a net result of DKK -144,214 compared with DKK -134,525 the year before. Equity in the 2025 report amounted to DKK -483,287.